Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 484 of 1,261

  1. US 10364238

    N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors

    KalVista Pharmaceuticals Limited · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  2. US 10364252

    Oxabicycloheptane prodrugs

    Lixte Biotechnology, Inc. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  3. US 10363244

    Compositions comprising metformin and a glucokinase activator

    VTV THERAPEUTICS LLC · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  4. US 10364431

    Compositions for treating muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  5. US 10363293

    Vaccine composition

    TURNSTONE LIMITED PARTNERSHIP · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  6. US 10364433

    Modulation of AGPAT5 expression

    The Regents of the University of California · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  7. US 10363245

    Methods for treating CNS lesions

    The Board of Regents of the University of Texas System · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  8. US 10364258

    Heteroaryl inhibitors of PDE4

    Tetra Discovery Partners · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  9. US 10363237

    Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase

    The Regents of the University of California · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  10. US 10363213

    Immunogenic composition against Campylobacter jejuni

    United States of America as represented by the Secretary of the Air Force · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  11. US 10363274

    Renal cell populations and uses thereof

    inRegen · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  12. US 10363247

    (S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer

    Karyopharm Therapeutics Inc. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  13. US 10363261

    Enolase inhibitors and methods of treatment therewith

    The Board of Regents of the University of Texas System · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  14. US 10363273

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Iovance Biotherapeutics, Inc. · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  15. US 10364275

    Methods for treating inflammatory responses or diseases caused by inflammation using ApoA-I binding protein (APOA1BP)

    The Regents of the University of California · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  16. US 10363282

    Analogs of C5a and methods of using same

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Jul 30, 2019 · Expires Jul 25, 2039

    granted

  17. US 2019224329

    Incremental Dose Finding in Controlled-Release PTH Compounds

    ASCENDIS PHARMA BONE DISEASES AS [DK] · Granted Jul 25, 2019 · Expires Jul 20, 2039

    granted

  18. US 10358501

    HER3 specific monoclonal antibodies for diagnostic and therapeutic use

    The Board of Regents of the University of Texas System · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  19. US 10357505

    Prodrugs of 2,4-pyrimidinediamine compounds and their uses

    Rigel Pharmaceuticals, Inc. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  20. US 10357464

    Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief

    The Board of Regents of the University of Texas System · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  21. US 10357477

    Anticancer compounds

    Regents of the University of Minnesota · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  22. US 10357553

    Compositions and methods for combination therapy with dengue virus and dendritic cells

    PrimeVax Immuno-Oncology · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  23. US 10358433

    Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity

    Theravance Respiratory Company, LLC · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

  24. US 10358495

    Anti-LAG3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 23, 2019 · Expires Jul 18, 2039

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.